Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor

Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST). However, the role of energy metabolism in imatinib-resistant GIST remains poorly characterized. Here, we investigated the effect of imatinib treatment on glycolysis and oxidative phosphorylation (OXPHOS), as well as the effect of inhibition of these energy metabolisms on cell viability in imatinib-resistant and -sensitive GIST cell lines. We observed that imatinib treatment increased OXPHOS in imatinib-sensitive, but not imatinib-resistant, GIST cells. Imatinib also reduced the expression of mitochondrial biogenesis activators (peroxisome proliferator-activated receptor coactivator-1 alpha (PGC1α), nuclear respiratory factor 2 (NRF2), and mitochondrial transcription factor A (TFAM)) and mitochondrial mass in imatinib-sensitive GIST cells. Lower TFAM levels were also observed in imatinib-sensitive GISTs than in tumors from untreated patients. Using the Seahorse system, we observed bioenergetics diversity among the GIST cell lines. One of the acquired resistant cell lines (GIST 882R) displayed a highly metabolically active phenotype with higher glycolysis and OXPHOS levels compared with the parental GIST 882, while the other resistant cell line (GIST T1R) had a similar basal glycolytic activity but lower mitochondrial respiration than the parental GIST T1. Further functional assays demonstrated that GIST 882R was more vulnerable to glycolysis inhibition than GIST 882, while GIST T1R was more resistant to OXPHOS inhibition than GIST T1. These findings highlight the diverse energy metabolic adaptations in GIST cells that allow them to survive upon imatinib treatment and reveal the potential of targeting the metabolism for GIST therapy.

[1]  S. Sleijfer,et al.  Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs , 2019, Cancers.

[2]  V. Calvo,et al.  Cisplatin resistance involves a metabolic reprogramming through ROS and PGC‐1&agr; in NSCLC which can be overcome by OXPHOS inhibition , 2019, Free radical biology & medicine.

[3]  K. Urbańska,et al.  Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells , 2019, International journal of molecular sciences.

[4]  G. Patti,et al.  Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation , 2019, eLife.

[5]  C. Larsson,et al.  miR‐125a‐5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors , 2018, Experimental cell research.

[6]  E. Giannoni,et al.  Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. , 2018, Cell metabolism.

[7]  C. Antonescu,et al.  Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor , 2017, Clinical Cancer Research.

[8]  Zhenfeng Zhang,et al.  Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer , 2017, Journal of Cancer.

[9]  D. Chitale,et al.  Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells , 2017, Scientific Reports.

[10]  T. Gibson,et al.  Metabolic shifts in residual breast cancer drive tumor recurrence , 2017, The Journal of clinical investigation.

[11]  Min Zhang,et al.  MICU1 drives glycolysis and chemoresistance in ovarian cancer , 2017, Nature Communications.

[12]  Zemin Zhang,et al.  Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation , 2017, Nature Communications.

[13]  Bernhard Kuster,et al.  Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis. , 2017, Cancer research.

[14]  Hengqiang Zhao,et al.  Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells , 2017, Journal of cellular and molecular medicine.

[15]  E. Wherry,et al.  Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. , 2016, Immunity.

[16]  C. Frezza,et al.  Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host , 2016, Cell reports.

[17]  G. Mills,et al.  Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. , 2016, The Journal of clinical investigation.

[18]  Y. Jo,et al.  Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production , 2016, Leukemia & lymphoma.

[19]  G. J. Yoshida Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of Experimental & Clinical Cancer Research.

[20]  C. Heeschen,et al.  MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. , 2015, Cell metabolism.

[21]  E. Ragazzi,et al.  Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death , 2015, Oncotarget.

[22]  J. Koster,et al.  SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer , 2015, Clinical Cancer Research.

[23]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[24]  C. Larsson,et al.  microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome , 2014, British Journal of Cancer.

[25]  P. Schumacker,et al.  Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.

[26]  L. Pusztai,et al.  Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential , 2014, Breast Cancer Research.

[27]  B. Kalyanaraman,et al.  Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation , 2014, British Journal of Cancer.

[28]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[29]  P. Puigserver,et al.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.

[30]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[31]  C. Frei,et al.  Nutrition Controls Mitochondrial Biogenesis in the Drosophila Adipose Tissue through Delg and Cyclin D/Cdk4 , 2009, PloS one.

[32]  Annick D. Van den Abbeele,et al.  The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging , 2008 .

[33]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Fletcher,et al.  Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. , 2006, Cancer research.

[35]  Shaomeng Wang,et al.  In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells , 2004, Clinical Cancer Research.

[36]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[37]  J. Fletcher,et al.  Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors , 2000, International journal of surgical pathology.

[38]  V. Mootha,et al.  Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.

[39]  M. Abou‐Donia,et al.  Metabolic fate of gossypol: the metabolism of [14-C]gossypol in swine. , 1975, Toxicology and applied pharmacology.

[40]  B. D. Myers,et al.  Effect of gossypol on some oxidative respiratory enzymes. , 1966, Plant physiology.

[41]  S. Weinhouse On respiratory impairment in cancer cells. , 1956, Science.

[42]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.